Clinical Trial Update: Inducing Systemic Immunity and Regressions in Metastatic Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update reports on a strategy to induce systemic immunity and observe tumor regressions in patients with metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: NYU Langone Health | Conditions: Metastatic Malignant Melanoma | Phase 1 | Status: COMPLETED